Respiratory disease

New survey shows Canadians want Big Tobacco to pay for tobacco reduction efforts

Retrieved on: 
Monday, May 29, 2023
Canadian Lung Association, Canadian Cancer Society, Smoker, Japan, American Cancer Society Cancer Action Network, Ipsos, Public, Parent, Tobacco, Policy, Stroke, Respiratory disease, Cancer, British Columbia v Imperial Tobacco Canada Ltd, American Cancer Society, Government, Organization, Outline, Big Tobacco, Health, Letter, Smoking, Death, Premier, Disease, Rothmans

The Canadian Cancer Society, Canadian Lung Association and Heart & Stroke are calling for significant tobacco reduction measures to be included in a major lawsuit settlement currently under negotiation with Big Tobacco companies.

Key Points: 
  • The Canadian Cancer Society, Canadian Lung Association and Heart & Stroke are calling for significant tobacco reduction measures to be included in a major lawsuit settlement currently under negotiation with Big Tobacco companies.
  • "We are deeply concerned that the negotiations are being held behind closed doors and that tobacco companies are at the table but health organizations are not.
  • The defendants are Imperial Tobacco Canada Ltd, Rothmans, Benson & Hedges Inc, and JTI-MacDonald Corp, as well as their foreign parents.
  • "A settlement must be about forever changing tobacco industry behaviour," says Terry Dean, President and CEO, Canadian Lung Association.

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

Retrieved on: 
Tuesday, May 23, 2023
PK, COPD, University, Senior, ATS, PRO, IDMC, COVID-19, Elastin, Research, Biomarker, Headache, Șaeș, EMA, University of Birmingham, Professor, Desmosine, Patient, NE, FDA, SVP, Respiratory disease, Conference, Caregiver, Safety, Pharmaceutical industry, Medical imaging

In line with previous guidance, Mereo is continuing to explore potential partnerships to fund the Phase 3 development of alvelestat.

Key Points: 
  • In line with previous guidance, Mereo is continuing to explore potential partnerships to fund the Phase 3 development of alvelestat.
  • Headache is a known adverse event associated with alvelestat and is being addressed through dose-escalation during initiation of alvelestat treatment.
  • The secondary endpoints were the proportion of patients with NE below the limit of quantitation and PK, safety and tolerability.
  • Exploratory endpoints included rate of acute exacerbations of COPD, pulmonary function tests, St George’s Respiratory Questionnaire, inflammatory and lung damage biomarkers.

Sonde Health's Respiratory Responsive Vocal Biomarker Tool Differentiates Patients with Respiratory Conditions from Healthy Individuals

Retrieved on: 
Tuesday, May 23, 2023
Technology, Health, Biometrics, Other Health, Pharmaceutical, Artificial Intelligence, Research, Medical Devices, Software, General Health, Health Technology, Science, Data Management, Medical Supplies, COPD, Deenanath Mangeshkar Hospital, Customer success, Asthma, UC San Diego Health, Albert Einstein College of Medicine, Senior, Journal of Medical Internet Research, COVID-19, Respiratory disease, Agency for Healthcare Research and Quality, Department of Medicine – University of Pamplona, Biomarker, Chronic obstructive pulmonary disease, Hospital, Journal, UC, Patient, Montefiore Medical Center, Data, Machine learning, Risk, AHRQ, JMIR, Pharmaceutical industry, Medical device, Brigham, Medicine

Sonde Health , a health technology company committed to bringing accessible health monitoring to everyone, has revealed new research that demonstrates the ability of its respiratory responsive vocal biomarker (RRVB) machine learning model to differentiate patients with COVID-19 from healthy individuals with about 70% accuracy.

Key Points: 
  • Sonde Health , a health technology company committed to bringing accessible health monitoring to everyone, has revealed new research that demonstrates the ability of its respiratory responsive vocal biomarker (RRVB) machine learning model to differentiate patients with COVID-19 from healthy individuals with about 70% accuracy.
  • The RRVB tool had already shown strong performance in differentiating patients with asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, and cough from healthy individuals.
  • These findings suggest the tool could help uncover respiratory conditions before symptoms arise.
  • The COVID-19 validation study tested this tool for its ability to differentiate patients with COVID-19 from healthy individuals with data collected from September 2020 through April 2021.

Medical Gases and Equipment Market to Reach $28.9 Billion, Globally, by 2032 at 7.6% CAGR: Allied Market Research

Retrieved on: 
Wednesday, May 17, 2023
COVID-19, Respiratory disease, Chart, Growth, Pandemic, PDF, Hospital, Page, Table, Health care, Medical device

PORTLAND, Ore., May 17, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Medical Gases and Equipment Market: By Product Type (Medical Gases, and Medical Gas Equipment), By Application (Therapeutic, Diagnostics, and Others), By End User (Hospitals, Ambulatory Surgical Centers, Diagnostic and Research Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2022-2032" According to the report, the global medical gases and equipment industry generated $14.3 billion in 2022, and is anticipated to generate $28.9 billion by 2032, witnessing a CAGR of 7.6% from 2023 to 2032.

Key Points: 
  • Due to the high demand for medical oxygen gas during COVID-19 pandemic, the medical gases and equipment market faced an excellent growth.
  • Procure Complete Report (416 Pages PDF with Insights, Charts, Tables, and Figures)
    The medical gases segment to maintain its leadership status throughout the forecast period.
  • Based on product type, the medical gases segment held the highest market share in 2022, accounting for nearly three-fourths of the global medical gases and equipment market revenue and is estimated to maintain its leadership status throughout the forecast period.
  • This is due to a rise in adoption of medical gases and increase in focus for the improvement of healthcare infrastructure.

Medical Gases and Equipment Market to Reach $28.9 Billion, Globally, by 2032 at 7.6% CAGR: Allied Market Research

Retrieved on: 
Wednesday, May 17, 2023
COVID-19, Respiratory disease, Chart, Growth, Pandemic, PDF, Hospital, Page, Table, Health care, Medical device

PORTLAND, Ore. , May 17, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Medical Gases and Equipment Market: By Product Type (Medical Gases, and Medical Gas Equipment), By Application (Therapeutic, Diagnostics, and Others), By End User (Hospitals, Ambulatory Surgical Centers, Diagnostic and Research Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2022-2032" According to the report, the global medical gases and equipment industry generated $14.3 billion in 2022, and is anticipated to generate $28.9 billion by 2032, witnessing a CAGR of 7.6% from 2023 to 2032.

Key Points: 
  • Due to the high demand for medical oxygen gas during COVID-19 pandemic, the medical gases and equipment market faced an excellent growth.
  • Procure Complete Report (416 Pages PDF with Insights, Charts, Tables, and Figures)
    The medical gases segment to maintain its leadership status throughout the forecast period.
  • Based on product type, the medical gases segment held the highest market share in 2022, accounting for nearly three-fourths of the global medical gases and equipment market revenue and is estimated to maintain its leadership status throughout the forecast period.
  • This is due to a rise in adoption of medical gases and increase in focus for the improvement of healthcare infrastructure.

Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection

Retrieved on: 
Wednesday, May 17, 2023
Medical Devices, Infectious Diseases, Defense, Health, Contracts, Duke University, Medicine, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, Respiratory disease, Organic compound, Infection, Volatile organic compound, COVID, Biomarker, Naval Aviation Warfighting Development Center, Exhaled breath condensate, Risk, Vaccine, FAIMS

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it had won an award from the U.S. Defense Innovation Unit (DIU), a division of the U.S. Department of Defense (DoD), for ‘Exhaled Breath Diagnostics’.

Key Points: 
  • Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it had won an award from the U.S. Defense Innovation Unit (DIU), a division of the U.S. Department of Defense (DoD), for ‘Exhaled Breath Diagnostics’.
  • The ‘EXHALE’ project, focused on the early detection of human infection using volatile organic compounds (VOCs) on breath, will develop a handheld device capable of non-invasive detection of pre-symptomatic respiratory infectious disease.
  • Warfighters routinely operate in remote environments where access to medical personnel is limited and the ability to diagnose infectious disease early is challenging.
  • The portable device by Owlstone will be adapted to work off battery power and detect VOCs present in exhaled breath, filling a gap in infectious disease detection.

Co-Diagnostics, Inc. to Host Booth at Senior Living Executive Conference in New Orleans, LA

Retrieved on: 
Tuesday, May 9, 2023
Argentum, Learning, COVID-19, Respiratory disease, PCR, SALT, Sale, Expo, RSV, Tuberculosis, Senior living, FDA, Conference, Pharmaceutical industry, Silver

The conference is the official meeting of Argentum, the leading national association exclusively dedicated to supporting companies operating professionally managed, resident-centered senior living, and is described as an opportunity to connect with thousands of executives and experts in the senior living space, with over 750 exhibiting companies and thousands of participants.

Key Points: 
  • The conference is the official meeting of Argentum, the leading national association exclusively dedicated to supporting companies operating professionally managed, resident-centered senior living, and is described as an opportunity to connect with thousands of executives and experts in the senior living space, with over 750 exhibiting companies and thousands of participants.
  • The Company's booth will showcase Co-Diagnostics' upcoming Co-Dx PCR Home™ testing platform and its planned pipeline of respiratory disease diagnostics, including COVID-19, influenza, RSV and tuberculosis.
  • More information about the conference may be found here .
  • Attendees interested in learning more about the Company and its upcoming Co-Dx PCR Home platform, which is subject to FDA review and is not available for sale, are invited to visit the Company's booth.

TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases

Retrieved on: 
Thursday, May 4, 2023
COPD, National Institute of Environmental Health Sciences, Asthma, TFF, SARS-CoV-2, Respiratory disease, CRADA, Pharmacokinetics, Research, Solubility, Respiratory syncytial virus, Government, Development, RSV, HMW, NIEHS, Roflumilast, Cystic fibrosis, Pharmaceutical industry, Dietary supplement

Today’s agreement follows prior research which showed that HMW-HA formulated with Thin Film Freezing yielded dry powder formulations that possess desirable aerosol performance.

Key Points: 
  • Today’s agreement follows prior research which showed that HMW-HA formulated with Thin Film Freezing yielded dry powder formulations that possess desirable aerosol performance.
  • Other indications may also be explored such as halogen-induced acute lung injury, acute and chronic lung allograft rejection, cystic fibrosis and asthma.
  • “However, due to physical limitations, many commercialized drugs cannot sufficiently reach their intended target, leading to suboptimal efficacy.
  • “Our preliminary results suggest that generation of hyaluronan powder via Thin Film Freezing has the potential to significantly improve upon current formulations of hyaluronan, which could have broad applications in the treatment of several respiratory diseases that are treatable by hyaluronan.

Handwashing During ‘Normal Times’ Can Reduce Burden of Respiratory Disease – Reckitt Global Hygiene Institute

Retrieved on: 
Friday, April 28, 2023
Professional Services, Environmental, Social and Governance (ESG), Health, Infectious Diseases, Fitness & Nutrition, General Health, Clinical Trials, Infection, Systematic review, WASH, URI, Pneumonia, Streptococcus, Norovirus, Hand, LRI, SARS-CoV-2, Public, Commission, ARI, COVID-19, Respiratory disease, Water, Sanitation, Research, LSHTM, Attention, Meta-analysis, Bill & Melinda Gates Foundation, Water supply, Government, Development, Death, Pandemic, Common, Tropical medicine, UN, Aris, Mass media, Disease, Bill, Mortality, Foreign, Commonwealth and Development Office, Bacteria, United, Commonwealth, Virus, London School of Hygiene and Tropical Medicine, Pharmaceutical industry, Vaccine, Medical device, Nursing, Renewable energy, Developing country, Hygiene, Lancet

Handwashing with soap can reduce cases of acute respiratory infection (ARI) in low- and middle-income countries (LMICs) by as much as 17%, according to a review published in The Lancet.

Key Points: 
  • Handwashing with soap can reduce cases of acute respiratory infection (ARI) in low- and middle-income countries (LMICs) by as much as 17%, according to a review published in The Lancet.
  • These findings, from one of the largest known meta-analyses to date on this topic, highlighted what the research team call a ‘missed opportunity’ to reduce the burden of respiratory disease.
  • The research, funded in part by the Reckitt Global Hygiene Institute (RGHI), reinforces the idea that efforts to encourage frequent and adequate hand hygiene must continue outside of pandemics.
  • The majority of those deaths are taking place in the world’s poorest countries,” said David Wheeler , Operations and Strategy Director, RGHI.

GigXR Awarded Air Force SBIR Phase II Contract to Develop Extended Reality (XR) Simulation Training for Department of the Air Force

Retrieved on: 
Wednesday, April 26, 2023
Technology, Contracts, Health Technology, Software, Government Technology, Training, General Health, Health, Education, Defense, Gig, Forward observers in the U.S. military, Checklist, Partnership, Miami Dade College, University, Bleeding, USAF, Nursing, Ursuline College, University of Leeds, Basic life support, SBIR, Anatomy, University Hospitals Cleveland Medical Center, Federal, Strategic planning, Explosion, Acquisition, Advanced cardiac life support, Patient, Respiratory disease, Gunshot, To Market, to Market (M*A*S*H), TCCC, Neurology, Injury, Cambridge University Hospitals NHS Foundation Trust, Phase, CUH, United States Air Force, ANIMA, BD, 68th Medical Group (United States), Elsevier

GigXR, Inc. , a global provider of holographic healthcare training, announced today that it has received a second Phase II Small Business Innovative Research (SBIR) contract to develop holographic simulation training for the 354th Medical Group United States Air Force (USAF) based out of Eielsen, Alaska.

Key Points: 
  • GigXR, Inc. , a global provider of holographic healthcare training, announced today that it has received a second Phase II Small Business Innovative Research (SBIR) contract to develop holographic simulation training for the 354th Medical Group United States Air Force (USAF) based out of Eielsen, Alaska.
  • GigXR will create high-stress, safe-to-fail situations that incorporate sounds, such as gunshots, explosions and helicopters overhead, to better mimic the experience of combat care.
  • “We are always extremely proud whenever we get to build something for the U.S. Military,” said Jared Mermey, CEO at GigXR.
  • “The mixed reality healthcare training that GigXR delivers is built to better prepare for what might be seen in the field.